<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479619</url>
  </required_header>
  <id_info>
    <org_study_id>010617</org_study_id>
    <nct_id>NCT03479619</nct_id>
  </id_info>
  <brief_title>Comparison of Three Lancing Devices Regarding Capillary Blood Volume and Lancing Pain Intensity.</brief_title>
  <official_title>COMPARISON OF THREE LANCING DEVICES REGARDING CAPILLARY BLOOD VOLUME AND LANCING PAIN INTENSITY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HTL-Strefa S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HTL-Strefa S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized single-blind study with the use of three lancing devices equipped with personal
      lancets. Every device will be studied for three lancet sizes: 28G, 30G, and 33G with the
      minimum and maximum puncture depth setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume (uL) of blood in the capillary tube</measure>
    <time_frame>1 - 3.5 hours (on average 2.5 hours) plus observation time after study 30 min</time_frame>
    <description>Examination of the volume of blood obtained after puncturing a fingertip with the use of 3 lancing devices set to minimum and maximum puncture depth, with the use of various-sized personal lancets (28G, 30G, and 33G).
The volume of blood sample will be measured with the use of capillary tubes calibrated for the volume of 10 Î¼l and a graduated ruler.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The intensity of pain perceived by the patient assessed with the use of the VAS (Visual Analog Scale).</measure>
    <time_frame>1 - 3.5 hours (on average 2.5 hours) plus observation time after study 30 min</time_frame>
    <description>Examination of the intensity of pain perceived when puncturing a fingertip with the use of 3 lancing devices set to minimum and maximum puncture depth, with the use of various-sized personal lancets (28G, 30G, and 33G).</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A/28/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 28 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/28/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 28 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/30/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 30 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/30/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 30 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/33/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 33 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A/33/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device A with personal lancet of size 33 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/28/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 28 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/28/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 28 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/30/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 30 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/30/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 30 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/33/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 33 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/33/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device B with personal lancet of size 33 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/28/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 28 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/28/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 28 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/30/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 30 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/30/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 30 G and maximum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/33/1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 33 G and minimum puncture depth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/33/5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lancing device C with personal lancet of size 33 G and maximum puncture depth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lancing device A</intervention_name>
    <description>Glucoject Dual Plus lancing device</description>
    <arm_group_label>A/28/1</arm_group_label>
    <arm_group_label>A/28/5</arm_group_label>
    <arm_group_label>A/30/1</arm_group_label>
    <arm_group_label>A/30/5</arm_group_label>
    <arm_group_label>A/33/1</arm_group_label>
    <arm_group_label>A/33/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lancing device B</intervention_name>
    <description>Droplet lancing device</description>
    <arm_group_label>B/28/1</arm_group_label>
    <arm_group_label>B/28/5</arm_group_label>
    <arm_group_label>B/30/1</arm_group_label>
    <arm_group_label>B/30/5</arm_group_label>
    <arm_group_label>B/33/1</arm_group_label>
    <arm_group_label>B/33/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lancing device C</intervention_name>
    <description>Commercially available lancing device</description>
    <arm_group_label>C/28/1</arm_group_label>
    <arm_group_label>C/28/5</arm_group_label>
    <arm_group_label>C/30/1</arm_group_label>
    <arm_group_label>C/30/5</arm_group_label>
    <arm_group_label>C/33/1</arm_group_label>
    <arm_group_label>C/33/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>28 G lancet</intervention_name>
    <description>Droplet 28 G</description>
    <arm_group_label>A/28/1</arm_group_label>
    <arm_group_label>A/28/5</arm_group_label>
    <arm_group_label>B/28/1</arm_group_label>
    <arm_group_label>B/28/5</arm_group_label>
    <arm_group_label>C/28/1</arm_group_label>
    <arm_group_label>C/28/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>30 G lancet</intervention_name>
    <description>Droplet personal lancet 30 G</description>
    <arm_group_label>A/30/1</arm_group_label>
    <arm_group_label>A/30/5</arm_group_label>
    <arm_group_label>B/30/1</arm_group_label>
    <arm_group_label>B/30/5</arm_group_label>
    <arm_group_label>C/30/1</arm_group_label>
    <arm_group_label>C/30/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>33 G lancet</intervention_name>
    <description>Droplet personal lancet 33 G</description>
    <arm_group_label>A/33/1</arm_group_label>
    <arm_group_label>A/33/5</arm_group_label>
    <arm_group_label>B/33/1</arm_group_label>
    <arm_group_label>B/33/5</arm_group_label>
    <arm_group_label>C/33/1</arm_group_label>
    <arm_group_label>C/33/5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lancing depth setting (1)</intervention_name>
    <description>The lowest depth setting (1)</description>
    <arm_group_label>A/28/1</arm_group_label>
    <arm_group_label>A/30/1</arm_group_label>
    <arm_group_label>A/33/1</arm_group_label>
    <arm_group_label>B/28/1</arm_group_label>
    <arm_group_label>B/30/1</arm_group_label>
    <arm_group_label>B/33/1</arm_group_label>
    <arm_group_label>C/28/1</arm_group_label>
    <arm_group_label>C/30/1</arm_group_label>
    <arm_group_label>C/33/1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lancing depth setting (5)</intervention_name>
    <description>The highest depth setting (5)</description>
    <arm_group_label>A/28/5</arm_group_label>
    <arm_group_label>A/30/5</arm_group_label>
    <arm_group_label>A/33/5</arm_group_label>
    <arm_group_label>B/28/5</arm_group_label>
    <arm_group_label>B/30/5</arm_group_label>
    <arm_group_label>B/33/5</arm_group_label>
    <arm_group_label>C/28/5</arm_group_label>
    <arm_group_label>C/30/5</arm_group_label>
    <arm_group_label>C/33/5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosed diabetes type 1 or 2 ,

          -  aged 18 - 50,

          -  period of suffering from diabetes &gt;2 years,

          -  performing on average 3-8 daily measurements of glycaemia,

          -  glycaemia at the moment of the beginning of the study between 70 and 200 mg/dl.

        Exclusion Criteria:

          -  glycaemia below 70 mg/dl or glycaemia above 200 mg/dl at the moment of the beginning
             of the study,

          -  previously diagnosed hemorrhagic diathesis or heavy bleedings in the past (also those
             without a medical diagnosis),

          -  anticoagulant (thrombolytic medication) therapy within 3 weeks prior to the study or
             on the day of the study,

          -  non steroidal anti-inflammatory drugs (NSAID) treatment 1 week prior to the study or
             on the day of the study,

          -  patients with signs of dehydration,

          -  patients who are currently participating in another clinical study,

          -  currently diagnosed or reported by the patient skin diseases, nervous system diseases,
             psychiatric diseases, etc., which, in the opinion of the person conducting the study,
             disqualify the patient from the participation in the study, in care for the patient's
             well-being.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Szadkowska, PhD,Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Lodz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ireneusz StaroÅ, MA</last_name>
    <phone>+48 785 911 593</phone>
    <email>ireneusz.staron@umed.lodz.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nzoz Magmed</name>
      <address>
        <city>Lodz</city>
        <zip>91-738</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Szadkowska</last_name>
      <phone>+48 42 656 79 31</phone>
      <email>agnieszka.szadkowska@umed.lodz.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lancing device</keyword>
  <keyword>lancet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

